A new study shows that patients who are prescribed opioids continue to use them over a long period of time, indicating potential abuse and adding fuel to the fire as lawmakers and industry groups continue to crack down on companies producing the drugs.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.
Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view.
It started in 2011 with just a handful of drugs. CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. Now, CVS' excluded list comprises almost 100 drugs and related products.
In 2011, CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. It was a pilot program, the pharmacy benefits manager said. Now, CVS' excluded list comprises almost 100 drugs and related products.
GlaxoSmithKline giant Advair may be reeling, but it hasn't kicked the bucket yet. And now, it's getting a payer boost that will breathe a little life into falling sales. With dismal second-quarter results depressing investors, the news couldn't have come at a better time.
Express Scripts has struck again. The pharmacy benefits manager is barring another 25 drugs, including some aging heavyweights like Amgen's anemia drugs Aranesp and Epogen, and newer meds such as the controversial painkiller Zohydro, made by Zogenix.
When do rising drug prices not equal rising sales? When payers step in to control costs--and that's exactly what they've been doing.
The FDA is getting an earful from another group intent on saving money on biotech drugs. A coalition of pharmacies, health insurers, unions and pension plans asked the agency to allow biosimilar drugs to carry the same generic names as the drugs they copy. Easy to substitute the biosim for the brand, easier to cut biotech drug spending.
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.